The worldwide rise in antibiotic resistance necessitates the development of novel antimicrobial strategies. Although many workers have used photodynamic therapy (PDT) to kill bacteria in vitro, the use of this approach has seldom been reported in vivo in animal models of infection. We have previously described the first use of PDT to treat excisional wound infections by Gram-negative bacteria in living mice. However these infected wound models used a short time after infection (30 min) before PDT. We now report on the use of PDT to treat an established soft-tissue infection in mice. We used Staphylococcus aureus stably transformed with a Photorhabdus luminescens lux operon (luxABCDE) that was genetically modified to be functional in Gram-positive bacteria. These engineered bacteria emitted bioluminescence allowing the progress of the infection to be monitored in both space and time with a lowlight imaging charged couple device (CCD) camera. One million cells were injected into one or both thigh muscles of mice that had previously been rendered neutropenic by cyclophosphamide administration. Twenty-four hours later the bacteria had multiplied more than one hundred-fold, and poly-L-lysine chlorin(e6) conjugate or free chlorin(e6) was injected into one area of infected muscle and imaged with the CCD camera. Thirty-minutes later red light from a diode laser was delivered as a surface spot or by interstitial fiber into the infection. There was a lightdose dependent loss of bioluminescence (to < 5% of that seen in control infections) not seen in untreated or light alone treated infections, but in some cases the infection recurred. Conjugate alone led to a lesser reduction in bioluminescence. Infections treated with free chlorin(e6) responded less and the infection subsequently increased over the succeeding days, probably due to PDT-mediated tissue damage. PDT-treated infected legs healed better than legs with untreated infections. This data shows that PDT may have applications in drug-resistant soft-tissue infections.
INTRODUCTION
Photodynamic therapy (PDT) uses the triple combination of a non-toxic dye known as a photosensitizer (PS), visible light (usually red), and oxygen to produce reactive oxygen species that cause cell death and tissue destruction 1 . It has gained clinical approvals to treat several forms of cancer, choroidal neovascularization in age-related macular degeneration, and actinic keratoses 2 . It has been known since the first days of PDT early in the last century that certain microorganisms can be killed by the combination of dyes and light in vitro 3 . At the present time the molecular characteristics of PS suitable for killing either Gram-positive or Gram-negative bacterial species (or both) are fairly well understood 3, 4 , but nevertheless, despite a century of using photodynamic inactivation (PDI) to kill bacteria in vitro, the use of PDT in vivo to treat infections has not been developed. The rapidly increasing emergence of antibiotic resistance amongst pathogenic bacteria is becoming a serious public health problem 5 . Bacteria replicate very rapidly and a mutation that helps a microbe survive in the presence of an antibiotic drug will quickly become predominant throughout the microbial population. The inappropriate prescription of antibiotics and the failure of some patients to complete their treatment regimen also exacerbate the problem. Antimicrobial resistance is becoming a factor in virtually all hospital-acquired (nosocomial) infections and physicians are concerned that several bacterial infections soon may be untreatable 6 . These concerns have led to major research effort to discover alternative strategies that could be used to combat infections in patients, such as naturally occurring antimicrobial peptides, bacteriophages and PDT. All studies that have examined in vitro PDI of antibiotic resistant bacteria have found them to be as equally susceptible as their naïve counterparts 7, 8 . In order to effectively treat infections with PDT in living animals certain conditions must be met. It is necessary to have selectivity of the PS for bacteria compared to host cells and tissue, a suitable route of administration of the PS to the infected area must exist, the infected area must allow effective light delivery, and an appropriate method of monitoring the result of treatment should be employed. Our approach to meeting these conditions is as follows. We use the covalent attachment of a PS (such as chlorin(e6), ce6) to polycationic peptides, such as poly-L-lysine (pL), to form a molecular-targeting vehicle that can bind to and penetrate both Gram-positive and Gram-negative bacteria 9, 10 . Because the resulting conjugate is a macromolecule, it should only be taken up by mammalian cells through the time-dependent process of endocytosis, thus giving a temporal selectivity for bacteria. The conjugate is directly administered by topical application or by injection directly into the infected area, and after a suitable interval to allow the PS to bind and penetrate the bacteria, light is delivered by surface illumination (or possible by interstitial fiber optic). We use genetically engineered bacteria that emit bioluminescence and can be detected in vivo using an intensified CCD camera 11 . By quantifying the bioluminescence images, the extent of infection can be determined in real-time in living animals providing both temporal and spatial information about the labeled bacteria 12, 13 . We previously showed that both a non-pathogenic strain of Escherichia coli 9 and a highly pathogenic strain of Pseudomonas aeruginosa 14 could be effectively and rapidly killed in excisional wounds in living mice 9 . In the latter case, PDT-treated mice were saved from death caused by the bacteria invading the bloodstream in mice whose wounds were untreated, or received light or conjugate alone 14 . However these experiments were carried on animals whose wounds were recently contaminated with relatively large numbers of CFU. It is unlikely that patients would present for treatment under these circumstances. A more realistic and clinically relevant model would consist of inoculation of a smaller number of bacteria and then allowing the infection to grow and become established in tissue over time. In this paper we report on the establishment of a soft-tissue infection model using stably transformed bioluminescent Staphylococcus aureus in mice who have been rendered temporarily neutropenic by cyclophosphamide administration. These infections were treated by direct injection of polycationic PS-conjugate into the infected area followed by illumination with red laser light.
MATERIALS AND METHODS

Preparation of polylysine-c e6 conjugate.
This was carried essentially as previously described 9 . Briefly, pL-HBr (average molecular weight = 22000, degree of polymerization = 110, Sigma Chemical Co, St Louis, MO) was dissolved in dry dimethyl sulfoxide (DMSO) to which was added ce6 (Porphyrin Products, Logan, UT) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Sigma). Triethylamine was then added and the mixture was stirred for 24 h, when methanol and water were added and the mixture was evaporated to dryness under vacuum. The residue was dissolved in sodium acetate buffer (10 mM, pH = 5.5), applied to a column of Sephadex G25 (60 × 1 cm) and eluted with the same buffer. Product containing fractions were collected and evaporated to give the product pL-ce6 with a substitution ratio of 7.4 ce6 per pL chain assuming the absorption coefficient of conjugated ce6 was the same as free ce6 (e400nm = 150,000 M-1cm-1).
Bacteria.
We used a strain of S. aureus (8325-4) that has been widely studied for pathogenicity and virulence factors 15 . Bioluminescent S. aureus were generated by transforming the strain 8325-4 with a modified Photorhabdus luminescens lux operon 16 using the Gram-positive lux transposon plasmid pAUL-ATn4001 luxABCDE KmR 17 which was introduced into the cells by electroporation as previously described 17 . Transformants were grown overnight in TSB containing erythromycin (5 µg/ml) and then plated onto TSB media containing kanamycin (200 µg/ml) to select for those clones where the Tn4001 luxABCDE KmR cassette had transposed and inserted downstream of a promoter. Highly bioluminescent colonies were selected using an IVISTM Imaging System (Xenogen Corporation, Alameda, CA). One clone, designated as S. aureus Xen 8.1, was selected and further characterized.
Mice.
All animal experiments were approved by the Subcommittee on Research Animal Care of Massachusetts General Hospital and were in accordance with NIH guidelines. Male Balb/c mice weighing 20-25 g were shaved on one or both back legs and depilated with Nair (Carter-Wallace Inc, New York, NY). Mice were anesthetized with an i.p. injection of ketamine/xylazine cocktail (90 mg/kg ketamine, 10 mg/kg xylazine) for infection, and for subsequent PDT and imaging.
Bioluminescence imaging.
The low light imaging system (Hamamatsu Photonics KK Bridgewater, NJ) has been previously described in detail 9 . It consisted of an ICCD camera mounted in a light-tight specimen chamber fitted with a light-emitting diode allowing a background gray-scale image of the entire mouse to be captured. In the photon-counting mode, an image of the emitted light was captured using an integration time of 2 min at a maximum setting on the image intensifier control module. Using ARGUS software the luminescence image was presented as a false-color image superimposed on top of the grayscale reference image. The image-processing component of the software gave total pixel values from the luminescence images on user-defined areas within each wound on a 256-grayscale. The analysis area was adjusted to cover the whole infection, and the resulting total pixel count was a combined measure of both the extent and intensity of infection. For calculation of total luminescence signals from each image, the values were normalized to a bit range of 2-4. For presentation of composite series of luminescence images the same bit range was used for each component image.
Infection model.
Initial studies were carried out to compare the growth of soft-tissue infections in normal and cyclophosphamidetreated mice. Mice were pre-treated with two separate doses of cyclophosphamide in order to create a temporary state of neutropenia. 150 mg/kg of cyclophosphamide (Sigma Chemical Co, St. Louis, MO) dissolved in sterile saline was injected IP (0.1 mL per mouse) on day 1, followed by a second dose of 100 mg/kg injected IP on day 4. One million mid-log phase bioluminescent S. aureus Xen 8.1 suspended in 50 mL PBS were injected 2-mm beneath the surface of the thigh muscle in normal and neutropenic mice (5 per group). Mice were anesthetized and were imaged with the luminescence camera immediately after infection and then after 4 hours and 24 hours and daily thereafter. They were monitored closely for symptoms of disease (weight, ruffled fur and inactivity) and mice that become moribund were sacrificed. In some mice we studied a model where both hind legs received an equal bacterial infection in each hind leg
Photodynamic therapy.
All experiments using mice that had been injected with PS were carried out under subdued room lighting or in the dark except when illumination was taking place. Mice were injected with pL-ce6 at a dose of 50-µL of a 1-mM ce6 equivalent solution into the area of subcutaneous and/or intramuscular infection. The area of infection was imaged using the bacterial bioluminescence in the Hamamatsu camera before injection so the infected area was known for each mouse. Injection was carried out using a 50-µL Hamilton syringe fitted with a 28-gauge needle. We injected 10-µL in the middle of the infected area and four additional 10µL aliquots of conjugate at the edges of the four quadrants of the infected area. Thirty minutes after conjugate injection, illumination was carried out by one of two methods. Both used a 1-W 665-nm diode laser (BWTek, Newark, DE) and 200-µm optical fibers coupled into the laser via SMA connectors. Surface illumination was accomplished by a fiber with a plane-polished distal end that provided a spot on the mouse leg with a diameter of up 1.5-cm. Interstitial light delivery was accomplished by inserting a fiber fitted with a spherical diffusing tip at the distal end into the infected area. The power was routinely measured using a laser power meter (model FM/GS, Coherent, Santa Clara, CA) and a power density of 100 mW/cm2 was employed for surface illumination and a power of 40 mW total out of the diffusing tip for interstitial light delivery Mice were imaged in the luminescence camera immediately before PS injection, immediately after the injections, and again after the 30-minute incubation time. Mice were again imaged after each increment of light dose had been delivered (this was frequently after each 40 J/cm2). In one set of experiments we treated mice with a single softtissue infection with PDT mediated by free (unconjugated) ce6. We injected 50-µL of a 1-mM solution of ce6 in PBS using the same methodology as for pL-ce6; i.e. 5 × 10-µL aliquots into the infection and after 30 minutes carried out surface illumination. Mice were imaged after each light dose and followed for healing as before.
Follow-up of mice.
Each day mice were weighed and imaged in the luminescence camera after brief anesthesia. Their legs were observed for function and marked on the following scale from 0 -4. 4 = perfectly normal leg in appearance and motion; 3 = slight limp, slight impairment in movement; 2 = significant impairment in movement, mouse cannot walk normally; 1 = leg is paralyzed and dragged behind mouse; 0 = legs suffers from frank necrosis or is absent. In addition the size of the visible lesion on the leg was measured in two dimensions using vernier calipers.
Statistics.
Differences between the means of lesion areas and leg function scores were analyzed for statistical significance by the unpaired 2-tailed Student's t test. P values < 0.05 were considered significant.
RESULTS
Normal versus neutropenic mice.
Since any clinical use of PDT for treatment of soft-tissue infections would be for patients that presented with an already established growth of bacteria in tissue, we wanted to test a model where the bacteria had been allowed to grow and multiply many-fold over time. We therefore compared the injection of 1 million log-phase S. aureus CFU into normal mice, and into those which had previously been rendered temporarily neutropenic by pre-treatment with cyclophosphamide. Typical time course sets of bioluminescence images from infected mice are shown in Figs 1a and 1b and the mean normalized bioluminescence values from 5 mice per group in Fig 1c. The normal mouse has lost all trace of bioluminescent bacteria by 6 hours after injection. By contrast the neutropenic mouse shows a greater than one-hundred-fold increase in signal 24 hours after infection and this remains at a very high level for a further 3 days. Mice frequently developed a whitish area on the skin at the location of the underlying infection after 24 h (Fig.1 d) . Significant amounts of bioluminescence were still present in the neutropenic mouse thighs for up to 18 days after infection. The cyclophosphamide treated mice exhibited symptoms arising from their infection (see next section) while the normal mice did not display any adverse effects. 
PDT of a 1-leg infection.
When the pL-ce6 conjugate (50-µL) at a concentration of 1-mM ce6 equivalent was injected into the infected area there was a visible green coloration noticeable beneath the skin (Fig 1e) . This allowed a judgment to be made about the uniformity of the PS distribution within the infection. Although these mice were neutropenic, and the infection did not accumulate the considerable quantities of pus expected from immunocompetent mice, there was still some matter present in the infection. This occasionally allowed the injected PS to flow within the tissue in unexpected ways so that an even distribution of green color was not seen. Another problem was that it was difficult to estimate the precise depth of infection from the luminescence image and sometimes it appeared the PS was injected above the majority of the bacteria if they happened to have penetrated some way into the muscle. We had previously suspected that the conjugate might diffuse relatively rapidly through the tissue, however this did not prove to be the case. The green coloration remained in place for some time (several hours) especially in unilluminated mice.
There was a slight reduction in bacterial bioluminescence observed immediately after the conjugate was injected into the infection. Luminescence was further reduced after the 30-minute incubation period in the dark. When illumination was commenced there was a light-dose dependent decrease in luminescence after each 40 J/cm2 increment of red light (Figs 2a and 2b) . In two of the mice (#2 and #3) at the completion of delivery of 160 J/cm2 the bioluminescence had declined to the limit of detection, and in these animals there was no regrowth of the bacteria as evidenced by imaging for the following days. In mouse 4 the response during light delivery was less impressive but the infection continued to decline over the 5 days following PDT and became undetectable. The remaining mice (#1 and #5) also had only a moderate response to light delivery, but these animals had an increase in the bioluminescence (indicating bacterial regrowth), which remained at moderate intensity for 10 days. As mentioned previously, infected mice showed symptoms arising from their infections 24 hours after injection of bacteria. They developed a white area visible on the skin of the thigh corresponding in location to the bioluminescence image. The legs of the mice showed impaired function ranging from a slight limp to complete paralysis. The means lesion sizes and leg function scores of control infected mice and infected mice that received PDT are shown in Figs 2c and 2d. The lesion size reached a peak on day 3 for both control and PDT treated mice, and for the next 8 days it appeared that the PDT lesions were somewhat larger than the control lesions (although this difference was not statistically significant). However on day 10 the PDT lesions had healed somewhat better than the control lesions and this difference became statistically significant (P<0.05) from days 17-22. The leg-function score reached a minimum on the day of PDT (24 hours after infection) for all mice, and then the PDT-treated legs began to improve faster than the control legs, and from day 7 until the end of the experiment the PDT treated legs performed significantly better than the controls (P<0.05). Four cyclophosphamide-treated mice were treated with PDT (injection of conjugate and 160 J/cm2 light) in the thigh muscle without injection of bacteria and therefore with no infection present. There was no visible lesion and no impairment of leg function seen at any time (data not shown). 
Combined interstitial and surface illumination.
We investigated the delivery of light into the infected area with an interstitial fiber fitted with a spherical-diffusing tip. We reasoned that the light was scattered by the overlying skin on top of the infection, thus decreasing the effective light dose that penetrated into area containing the bacteria. In preliminary experiments we tried interstitial illumination alone, and delivered a defined fluence, removed the mouse, imaged it in the camera, reinserted the fiber and delivered a further increment of light from the interstitial fiber. However we observed that the reduction in bacterial bioluminescence seen after the first increment of interstitial light had been delivered, was not replicated after the second and any subsequent increments. Although the reason for this observation is not obvious, it may have a connection to the repeated punctures of the infected necessary to reinsert the fiber after imaging. We then decided to deliver the interstitial light in one increment of 18J total out of the fiber at a power of 40 mW, withdraw the fiber, image the mice and then deliver two further increments of light (60 J/cm2) each by surface illumination. This sequence gave superior results to those obtained with light delivery in reverse order (surface first, followed by interstitial, data not shown). The mean bioluminescence values are shown in Fig 3, and it can be seen that the mean bioluminescence signal was reduced by 99% after these three light increments. However, in all these 5 mice there was regrowth of the bioluminescence signal on the day after PDT, and by the next day the intensity had almost reached pre-treatment levels. This regrowth in infection then slowly declined over the next 2 weeks. 
Comparison with free ce6.
In a previous publication 10 we showed that free ce6 was significantly better than pL-ce6 conjugate in mediating the light-dependent killing of S. aureus in vitro. To test our hypothesis that selectivity of the polycationic PS conjugate for bacteria over host tissue was important in PDT of soft tissue infections we repeated the experiment involving treatment of a single soft tissue infection, by injecting a solution of free ce6 into the infection followed by superficial illumination. As depicted in Figure 4 , there was a reduction in luminescence observed 30 minutes after the PS had been injected into the infected area, and the light-dose dependent reduction in luminescence after each surface-delivered increment of 40 J/cm2 (although significant) was less than was seen with pL-ce6 (amounting to only approximately 80%). All the mice displayed an increase in the bioluminescent signal on the following day ( Figure 4) . Figure 4. Mean total normalized bioluminescence values from thighs of 5 infected mice treated with PDT by injection of pL-ce6 conjugate into the infection, followed after 30 min by insertion of a diffusing-tipped fiber into the infection and delivery of 18 J of 665-nm light at a fluence rate of 40 mW, and then surface illumination as described. Bars are SEM.
Model with infections in both legs.
In an attempt to control for significant variations in the intensity of the bioluminescent signals from the infections between individual mice, we studied a model where the mice received an equal bacterial inoculation in each thigh muscle. We reasoned that the PDT-dependent reduction in bioluminescent signal should be easier to quantify if each mouse had a treated and an untreated infection. A typical mouse treated with injection of conjugate into the right infected thigh, followed by illumination of this thigh as described previously is shown in Fig 5a, together with the mean bioluminescence values from both legs of 5 mice in Fig 5b. After 160 J/cm2 had been delivered the bioluminescence of the treated infected legs had been reduced by >99% compared to the untreated contralateral legs. However 4 out of 5 of these treated legs suffered a recurrence of the bioluminescence on succeeding days (data not shown). 
DISCUSSION
The results of the present study have shown the proof-of-principle that PDT can be effectively used to treat an established soft-tissue infection in living mice. However the methodology contains considerable challenges and significant improvements will need to be made before it could be considered for clinical application. Although mice have been extensively employed as animal models of bacterial infection 10, 18 , they are not particularly susceptible to developing established soft tissue infections. When Francis et al studied 16 bioluminescent S. aureus 8325-4 (5 × 10 6 CFU containing a plasmid based lux operon) injected into the thigh muscles of mice, they found that although the bioluminescent signal was higher at 4 h than immediately after injection, it subsequently declined over the next 20 h. Since we wanted to treat an established soft-tissue infection, (i.e. one in which the bacteria had multiplied many times in the tissue using their virulence factors to adhere to tissue and obtain their nutrients) we tested the use of systemic cyclophosphamide to precondition the mice by inducing temporary granulocytopenia 19 . The bacteria were injected into to the superficial layers of the thigh muscle and subsequently spread into the subcutaneous space and from days 2 to 5 bioluminescence imaging showed a >100-fold increase in both bacterial density and the overall size of the infection. The experiments illustrate the benefits of using bioluminescent bacteria and a low-light imaging system to quantify bacterial numbers in tissue in real-time, and the ability to longitudinally follow the progress of the infection in individual mice. The fact that the bacteria were stably transformed with the bacterial lux operon, as opposed to possessing the genes necessary for light generation on a plasmid, gave added assurance that variations in bioluminescence seen over extended periods was due to variations in bacterial numbers, rather than a slow loss of the plasmid due to pressure of growth selection.
(a) (b)
Choosing the optimal parameters for treating an established soft-tissue infection by PDT is inherently complex. The identity of the PS, the concentration and volume of the injection into the infection and the number of injections needed to achieve an equal spatial spread of the PS throughout the infected area are crucial. In addition the time between PS injection and illumination, the mode of light delivery (surface spot versus interstitial fiber placement), fluence rate and total delivered fluence are highly important variables. One major problem we encountered was the regrowth of the infections as monitored by the bioluminescent signal after PDT-mediated reductions greater that 95%. It could be argued that a rapid reduction in infectious bacterial burden is valuable in its own right, and subsequent bacterial re-growth could be prevented by administration of systemic antibiotics, which are generally thought to be more efficient in achieving bacteriostasis than actively killing large numbers of bacteria. However, then one of the main attractions of using PDT for infections, that it is effective against multiply-antibiotic resistant strains, would be somewhat negated. Although the results measuring the reduction of the lesion size and the improvement in leg function scores did not show a dramatic benefit due to PDT, there was nevertheless a statistically significant improvement in both parameters in the PDT-treated infected legs compared to untreated controls. PDT alone carried out on non-infected cyclophosphamide treated mice did not lead to any lesion or any adverse effects thus demonstrating that under these conditions damage to host tissue was not observed solely due to PDT. The comparative improvement in healing of the legs in infected mice due to PDT, despite the observed recurrence of infection, may be due to the PDT-induced inflammatory response accelerating healing, or to the ability of PDT to destroy secreted bacterial virulence factors that slow down healing 20 .
We have shown some evidence that the success of the treatment depends on killing bacteria without causing damage to host tissue. This is illustrated in the experiments using free ce6, which we had previously shown 10 to be superior to pL-ce6 in mediating PDI of S. aureus in vitro. In these mice PDT after injection of ce6 into the infection led to only a small decrease in the bioluminescence in the infection and all mice subsequently showed a regrowth of the bacteria over the following days. One can speculate that free ce6 (although highly effective against S. aureus in vitro) does not show enough selectivity for bacteria over mammalian cells because it is a small molecule with an overall anionic character. When it is injected into the infection, if it was chiefly taken up by mouse cells and only to a lesser degree by the bacteria, upon illumination it would tend to cause host tissue damage, together with a reduced antibacterial effect. Since fewer of the bacteria are killed and the host tissue is damaged, this combination would provide an ideal breeding ground for bacterial regrowth. However further studies comparing leg function, healing time and histological analysis between PDT of infections mediated by conjugate and mediated by free ce6 would be necessary to confirm this hypothesis. There was also more marked bacterial regrowth after the interstitial followed by surface illumination. Again it is possible that insertion of the fiber into the infection causes sufficient tissue damage to encourage regrowth of bacteria. Berthiaume et al. 21 evaluated the efficacy of antibody-targeted photolysis to kill bacteria in vivo using PS immunconjugates against P. aeruginosa. Initially they mixed the bacteria with the tin (IV) chlorin e6-monoclonal antibody conjugate in vitro, and injected the mixture into the subcutaneous dorsal area in mice. After infecting with both specific and nonspecific were injected at the infection site. After a 15-min incubation period, the site was exposed to 630 nm light with a power density of 100 mW/cm2 for 1600 seconds. Illumination resulted in a greater then 75% decrease in the number of viable bacteria at sites treated with a specific conjugate, whereas normal bacterial growth was observed in animals that were untreated or treated with a nonspecific conjugate. The only report of PDT being used to treat localized bacterial infections in patients was published by Lombard et al 22 . They treated 5 patients with brain abscesses after craniotomy and surgical drainage by instilling hematoporphyrin into the abscess bed and illuminating 5 minutes afterwards to give a positive clinical response. S. aureus is responsible for diseases such as pyoderma, toxic shock syndrome and wound and burn infections in hospital patients. It has attracted much attention recently due to its acquired antibiotic resistance. It is a major cause of infections in surgical patients and is frequently transmitted to wounds from colonies that have become established in the noses either of patients or of hospital workers. Strains of S. aureus resistant to methicillin and other antibiotics are endemic in hospitals 23 . Infection with methicillin-resistant S. aureus (MRSA) strains may also be increasing in non-hospital settings. Methicillin resistant S. aureus strains with reduced susceptibility to vancomycin have emerged recently in Japan and the United States and present a serious problem for physicians and patients 24 . PDT could provide an alternative to surgical debridement and topical antimicrobials for these otherwise hard to treat wound and tissue infections.
